ACADIA
Pharmaceuticals Inc. (Nasdaq: ACAD) delayed the submission of a New Drug
Application for its Parkinson's disease psychosis treatment NUPLAZID
until the second half of 2015 and announced the immediate retirement of
chief executive Uli Hacksell, Ph.D. The stock price plummeted $10.13 to $34.63.
ACADIA delays NDA filing
March 12, 2015 at 13:46 PM EDT
